OverviewChartNewsTraderScreen

Morgan Stanley Call 60 INCY 20.12.../  DE000ME9H2Y1  /

Stuttgart
2024-04-26  9:28:43 PM Chg.+0.13 Bid10:00:35 PM Ask10:00:35 PM Underlying Strike price Expiration date Option type
1.34EUR +10.74% -
Bid Size: -		 -
Ask Size: -		 Incyte Corporation 60.00 USD 2024-12-20 Call
GlobeNewswire 04-02 HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sin...
GlobeNewswire 04-01 CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast ...
GlobeNewswire 02-28 Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Up...
GlobeNewswire 01-09 Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
TeleTrader 2023-12-12 Wall Street closes higher after inflation report
GlobeNewswire 2023-12-09 CURE Media Group announces winners of the 2023 MPN Heroes® Recognition Program
GlobeNewswire 2023-11-16 CURE Media Group® announces Jane Fonda as keynote speaker for the 2023 MPN Heroes® recognition progr...
GlobeNewswire 2023-11-02 Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
GlobeNewswire 2023-10-23 Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President...
GlobeNewswire 2023-10-12 Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
GlobeNewswire 2023-09-27 Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
TeleTrader 2023-09-18 Wall Street opens mostly lower, Fed anticipation builds up
GlobeNewswire 2023-08-28 Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
TeleTrader 2023-02-07 Wall Street back to losses, Dow slides 200 points
TeleTrader 2023-02-07 US markets lower amid economic data, Fed's Powell
GlobeNewswire 2022-03-23 RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation An...
GlobeNewswire 2022-03-14 STRATA Skin Sciences Names John Bagdasarian as Vice President of Professional Relations
GlobeNewswire 2022-03-01 Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus R...
GlobeNewswire 2022-02-28 Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Up...
GlobeNewswire 2022-02-24 MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
GlobeNewswire 2022-01-25 Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
GlobeNewswire 2022-01-10 Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agre...
GlobeNewswire 2021-12-15 AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation...
GlobeNewswire 2021-12-11 Annual Changes to the Nasdaq-100 Index®
GlobeNewswire 2021-12-06 Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021